Tumor microenvironment (TME) plays an active role in promoting tumor progression. To further understand the communication between TME and tumor cells, this study aimed at investigating the involvement of CD44, a type I cell surface receptor, in the crosstalk between tumor cells and TME. We have previously shown that chondroitin sulfate proteoglycan serglycin (SRGN), a CD44-interacting factor, was preferentially secreted by cancer-associated fibroblasts (CAFs) for promoting tumor growth in breast cancer patients. In this study, we show that SRGN is overexpressed in primary non-small cell lung cancers (NSCLCs), by both carcinoma and stromal cells. Using gain-of-function and loss-of-function approaches, we show that SRGN promotes NSCLC cell migration and invasion as well as colonization in the lung and liver in a CD44-dependent manner. SRGN induces lung cancer cell stemness, as demonstrated by its ability to enhance NSCLC cell sphere formation via Nanog induction, accompanied with increased chemoresistance and anoikis-resistance. SRGN promotes epithelial-mesenchymal transition by enhancing vimentin expression via CD44/NF-κB/claudin-1 (CLDN1) axis. In support, CLDN1 and SRGN expression are tightly linked together in primary NSCLC. Most importantly, increased expression of SRGN and/or CLDN1 predicts poor prognosis in primary lung adenocarcinomas. In summary, we demonstrate that SRGN secreted by tumor cells and stromal components in the TME promotes malignant phenotypes through interacting with tumor cell receptor CD44, suggesting that a combined therapy targeting both CD44 and its ligands in the TME may be an attractive approach for cancer therapy.
INTRODUCTION
Tumor microenvironment (TME) plays an important role in cancer formation and progression. Activated fibroblasts, also known as cancer-associated fibroblasts (CAFs), [1] [2] [3] are the abundant component of tumor stroma. CAFs have been reported to function as an important tumor promoter by secreting a cohort of growth factors and cytokines to enhance tumor growth, 4, 5 angiogenesis, 6 ,7 metastasis, 8 epithelial-mesenchymal transition (EMT) [9] [10] [11] and stemness. [10] [11] [12] [13] In addition, cancer cells have been demonstrated to reinforce their malignant behaviors by promoting the conversion of normal fibroblasts to CAFs through reactive oxygen species-and transforming growth factor-β-mediated mechanisms.
14 However, the molecular mechanism(s) underlying CAF-elicited malignancy remains largely unclear.
CD44, a type I transmembrane glycoprotein, mediates the response of cells to the microenvironment in the regulation of lymphocyte homing, inflammation, tumor growth and metastasis. 15 We have previously shown that osteopontin binds to CD44 and osteopontin-mediated ligation of CD44 enhances cell survival in gastrointestinal cancer cells. 16, 17 CD44 isoforms interact with hepatocyte growth factor and vascular endothelial growth factor and regulate c-MET and fibroblast growth factor receptor 2-mediated signaling pathways. 18, 19 These data suggest that tumor cell surface receptor CD44 may act as a crucial mediator in the crosstalk to the microenvironment. In this study, we aimed at investigating the role of CD44 in mediating the crosstalk between tumor cells and TME, in particular in response to CAFselicited paracrine pathways.
Serglycin (SRGN), a hematopoietic cell granule proteoglycan, serves as a novel ligand for CD44 in lymphocyte activation. 20 We have recently shown that SRGN was secreted at the higher amount by human breast CAFs. 8 Overexpression of SRGN was found in nasopharyngeal carcinoma (NPC) and breast carcinoma, 21, 22 and high levels of SRGN were also found in the sera of hepatocellular carcinoma patients with bone metastasis 23 and in the bone marrow aspirates of multiple myeloma patients. 24 Notably, elevated SRGN level was correlated with poor survival and recurrence of NPC and hepatocellular carcinoma patients. 21, 25 These studies suggest that secreted SRGN may promote cancer malignancy; however, the underlying mechanisms remain to be explored.
In this study, we demonstrated that SRGN is overexpressed in non-small cell lung cancers (NSCLC), and SRGN promotes NSCLC aggressiveness. We showed that SRGN enhances NSCLC malignancies via facilitating EMT through CD44/NF-κB/claudin 1 (CLDN1) axis. In support, expression of SRGN and CLDN1 is tightly associated in primary NSCLC and predicts poor survival of patients with lung adenocarcinomas.
RESULTS

SRGN is overexpressed in primary lung cancer
We have previously shown that SRGN, a CD44-interacting proteoglycan, is frequently overexpressed in CAFs in breast cancer patients. 8 SRGN has also been reported to be overexpressed in the carcinoma cells of aggressive NPC 21 and breast cancer. 22 To examine whether SRGN was expressed in other types of cancer, we measured SRGN transcripts in 41 cancer cell lines across six different tumor types by quantitative reverse transcription polymerase chain reaction analysis. Among the carcinoma cell lines, SRGN was expressed at significantly higher levels in breast cancer-and NSCLC-derived cell lines (Figure 1a) . We also measured the absolute amounts of SRGN secreted in the medium in various cell lines by ELISA assay. As shown in Supplementary Figure S1 , the amounts of SRGN secreted to the CM correlated to the levels of its transcripts. We further performed in silico analysis of lung cancer stromal complementary DNA (cDNA) expression data (GSE33363) and showed that SRGN was also highly expressed by the stromal cells in primary lung cancers (Figure 1b) . By quantitative reverse transcription polymerase chain reaction analysis of SRGN expression in the tumor and non-tumorous tissues derived from seven patients with lung adenocarcinoma, we showed that subset of primary lung adenocarcinomas displayed significantly high levels of SRGN (Figure 1c ). Immunohistochemistry confirmed that SRGN was highly expressed by the tumor cells and stromal components in primary lung adenocarcinomas ( Figure 1d ).
SRGN promotes lung cancer cell aggressiveness To explore whether SRGN plays an oncogenic role in lung malignancy, gain-and loss-of-function approaches were taken. We overexpressed SRGN in NSCLC-H1299 cells that express endogenous SRGN at very low level. SRGN was readily secreted to the conditional medium (CM) as a proteoglycan heavily decorated with chondroitin sulfate as evidenced by the dramatic decrease in the molecular weight after the treatment with chondroitinase ABC, an enzyme cleaving the chondroitin sulfate-linkage (Supplementary Figures S2a and b) . H1299 cells stably expressing ectopic SRGN displayed increased abilities in cell migration and invasion (Figure 2a ), colony formation in soft agar (Figure 2b ), and tumor cell colonization in the lung and liver in NOD-SCID IL2Rγ null (NSG) mice (Figures 2c and d) . To demonstrate that SRGN drives the aggressive phenotypes, we transiently transfected H1299 cells with increasing amounts of vector encoding SRGN, and showed that increased cell motility was correlated to the levels of SRGN (Supplementary Figure S2c) . Reciprocal experiments were performed to knockdown the expression of SRGN in NSCLC H460 and A549 cells using lentivirus-based shRNA approach. The efficiency of gene knockdown (KD) was confirmed by quantitative reverse transcription polymerase chain reaction and western blot analyses (Supplementary Figure S3) . In consistence, KD of SRGN suppressed cell migration and invasion (Figure 2e) , and anchorageindependent growth (Figure 2f ). Depletion of SRGN greatly suppressed the ability of NSCLC cells in xenograft tumor growth ( Figure 2g ) and tumor cell colonization in the lung of nude mice (Figure 2h ).
CD44 is required for SRGN-elicited malignant phenotypes in NSCLC cells
To examine the role of CD44 in SRGN-elicited malignant phenotypes, we enriched CD44-negative (CD44-) cells from H1299 cells via three rounds of fluorescence-activated cell sorting (FACS) procedure (Figure 3a) . Western blotting showed the levels of CD44 in the individual populations of sorted cells (Figure 3b) , and in the sorted CD44(− ) and unsorted parental H1299 cells stably harboring the control and SRGN-expression vectors ( Figure 3c ). As shown, SRGN elicited cell migration and invasion (Figure 3d ), and in lung and liver colonization (Figure 3e ) in the CD44-proficient, but not CD44-deficient cells. Rescue experiments were performed by re-introducing the standard form of CD44 (CD44s) into H1299 CD44( − ) cells, and re-expression of CD44s restored SRGN-mediated migration (Figure 3f ). These results suggested that SRGN promotes NSCLC malignant phenotypes in a CD44-dependent manner.
In addition to H1299 CD44( − ) cells, we further validated the functional interaction between SRGN and CD44 in duodenal adenocarcinoma HTB-40 cells that expressed endogenous CD44 at undetectable level. As shown, incubation with SRGN-containing CM or recombinant human SRGN significantly enhanced migration in HTB-40/CD44s cells, but not in HTB-40/Mock cells (Figures 3g and h) . These results suggest that secreted SRGN may interact with cell surface receptor CD44 and promote malignant phenotypes.
SRGN promotes NSCLC cells stemness via Nanog induction, leading to increased chemo-and anoikis-resistance in a CD44-dependent manner.
Since CD44 is a signature of NSCLC stem cells, 26 we investigated whether SRGN may modulate NSCLC cell stemness via interacting with CD44. As shown, ectopic expression of SRGN significantly enhanced sphere formation in H1299 cells (Figure 4a ), accompanied with increased expression of Nanog (Figure 4b ). On the other hand, KD of SRGN greatly suppressed sphere formation in H460 cells (Figure 4c ), along with a blunt reduction in the expression of Oct4, Sox2 and Nanog ( Figure 4d ). Nanog is critical for SRGN-modulated stemness because KD of Nanog completely abolished SRGN-elicited sphere formation in H1299/SRGN cells ( Figure 4e ). We further showed that cells deficient in CD44 failed to respond to SRGNmediated Nanog induction ( Figure 4f ) and sphere formation (Figure 4g ), and that re-introduction of CD44s into CD44( − ) cells restored SRGN-elicited Nanog expression ( Figure 4h ) and sphere formation (Figure 4i ), suggesting that SRGN promoted NSCLC cell stemness via Nanog induction in a CD44-dependent manner. SRGN has been shown to compete with hyaluronic acid (HA) for CD44 binding. 20 Figure 4j shows that anti-CD44 antibody (5F12) that blocks HA/CD44 interaction efficiently blocked SRGN-mediated Nanog expression in H1299/SRGN and H460/sh-Scram cells, suggesting that SRGN interacts with cell surface CD44 to elicit NSCLC cells stemness via Nanog-induction. In consistence to the increased stemness, H1299/SRGN cells displayed increased resistance to cisplatininduced cytotoxicity at dose-and time-dependent manners ( Figure 4k ). Moreover, overexpression of SRGN led to an increased resistance to anoikis in H1299 cells, whereas depletion of SRGN sensitized H460 cells to anoikis (Figure 4l ). SRGN elicits NSCLC aggressiveness mediated through claudin-1 expression Induction of EMT has been reported to generate stem-like cells, 27 and also confers increased capacity of cell migration and tumor metastasis. 28 We examined whether SRGN promotes EMT in NSCLC. As shown in Figure 5a , ectopic expression of SRGN increased the expression of vimentin in H1299 cells, whereas KD of SRGN led to decreased expression of vimentin in H460 and A549 cells. Notably, the expression of tight junction protein CLDN1 was correlated to the expression of vimentin in SRGN-overexpressing and -depleted cells. CLDN1, a protein generally considered as an epithelial marker, has recently been reported to be overexpressed and induce EMT and metastatic behaviors in colorectal carcinomas 29 and hepatocellular carcinoma. 30 Here, we showed that ectopic expression of CLDN1 significantly up-regulated the expression of vimentin in H1299 cells (Figure 5b ), and KD of CLDN1 using two individual shRNAs led to significant suppression of SRGN-elicited vimentin expression ( Figure 5c ). These data strongly suggested that SRGN-induced vimentin expression was mediated through CLDN1 expression. We then examined whether CLDN1 plays a role in SRGN-elicited NSCLC aggressiveness. cis-elements corresponding to the consensus binding sites for various transcription factors including NF-κB were identified in CLDN1 promoter. As TNFα has been reported to induce CLDN1 expression and promote EMT in lung cancer cells, 31 we examined whether SRGN induced CLDN1 expression via NF-κB activation. Using reporter assay, we showed that ectopic expression of SRGN increased NF-κB promoter activity (Figure 6a ). In consistence, overexpression of SRGN decreased IκBα protein level in H1299 cells, and KD of SRGN led to accumulation of IκBα protein in H460 cells (Figure 6b ). Most importantly, inhibition of NF-κB activation by ectopic expression of dominant-negative (DN) IKKα/β abolished SRGN-mediated claudin-1 expression, accompanied with a concomitant increase in the level of IκB protein (Figure 6c ). These results suggested that SRGN-induced CLDN1 expression was mediated through NF-κB activation. We further showed that SRGN promoted p65 nuclear translocation in CD44-proficient, but not in CD44-deficient H1299 cells (Figure 6d) . As a consequence, SRGN failed to elicit CLDN1 expression in CD44( − ) cells SRGN-CLDN1 axis predicts poor survival in lung cancer patients We further assessed clinical implications of SRGN and CLDN1 by immunohistochemistry of SRGN and CLDN1 in 81 patients with resectable NSCLC. SRGN staining was detected in the carcinoma cells of 39 NSCLC, including 27 tumors stained positive in both carcinoma and stromal cells (Figure 1d ). In addition, another 15 NSCLC were stained positive for SRGN but only in the stromal component (Supplementary Figure S4b) . CLDN1 expression was detected in 40 NSCLC, mainly in the cytosol and/or nucleus. A strong association of SRGN and CLDN1 expression was observed in these patients (P o0.001; Table 1 and Supplementary  Figure S4a) . Kaplan-Meier survival analysis showed that SRGN expression was associated with poor overall survival (HR = 2.068, CI = 1.111-3.848, P = 0.028; Figure 7a ). The prognostic role of CLDN1 was not evident in this subset of patients. We further examined the prognostic role of SRGN-CLDN1 axis in a large set of lung adenocarcinomas (n = 720) by meta analysis using the online Kaplan-Meier plotter (www.kmplot.com/lung). 32 In consistence, patients with lung adenocarcinoma expressing SRGN transcripts at high level displayed poorer survival (HR = 1.878, CI = 1.454-2.425, P o0.0001; Figure 7b , top panel). In addition, high CLDN1 expression was also associated with poor survival (HR = 1.753, CI = 1.328-2.314, P o 0.0001; Figure 7b , middle panel). When patients were stratified into four groups according to the expression of SRGN and CLDN1, patients with tumors expressing high levels of SRGN or CLDN1 displayed poorer survival, and only the group of patients expressing both SRGN and CLDN1 at low levels displayed significantly better survival (P o 0.001; Figure 7b , bottom panel).
In summary, this study provides a novel working model for the crosstalk of tumor cells and TME (Figure 7c) . SRGN secreted by NSCLC cells and/or CAFs in the TME can interact with tumor cell receptor CD44 to promote malignant phenotypes through eliciting stemness by Nanog induction, and enhancing EMT through NF-κB-mediated CLDN1 induction.
DISCUSSION
Accumulating evidence has demonstrated an active role of tumor stroma in fostering tumor formation and progression. osteopontin and hepatocyte growth factor are among the factors highly expressed by CAFs, 5, 33 and both have been demonstrated to bind to tumor cell surface receptor CD44 and transduce signals to regulate cancer cell proliferation, survival, migration and invasion, 16, 34, 35 We have previously identified proteoglycan SRGN, a CD44-interacting factor, secreted by CAFs in breast cancer patients. 8 In this study, we further show that SRGN is overexpressed in human lung cancer and that SRGN promotes aggressive phenotypes of NSCLC cells via its interaction with CD44.
Proteoglycans, a major species of macromolecules abundantly present in the ECM, have been shown to influence cancer development and metastasis. SRGN, a chondroitin sulfate (CS)-proteoglycan initially identified in the secretary granules of hematopoietic cells, was shown to be readily exocytosed and then bind to CD44 to promote lymphoid cells adhesion and activation. 20, 36 SRGN has recently been shown to be overexpressed in several aggressive cancer types, including NPC, breast cancer, hepatocellular carcinoma and myeloma. 21, 22, 24, 25, 37 By examining SRGN expression across various types of cancer cells, in this study, we showed that SRGN was expressed at significantly elevated levels in breast and lung cancer cell lines, as compared with colon and gastric cancer cell lines. We also noted that the levels of SRGN expression in several NSCLC cells were significantly higher than that of immortalized human bronchial epithelial cells (HBEC3-KT or 3KT) and K-RASV12-transformed HBEC3-KT cells (3KTR), implicating an oncogenic role of SRGN in lung malignancy. To clarify the cell types that overexpress SRGN in lung carcinomas, we performed in silico analysis of the expression profiles of microdissected NSCLC tumor cells and the stromal components (GSE33363), 38 and showed that SRGN was also highly expressed by the stromal components of primary lung cancers. By immunohistochemistry, we showed that SRGN was overexpressed in both carcinoma and stromal cells in primary lung adenocarcinomas. We proposed that SRGN may work through both paracrine and autocrine signals to promote malignant transformation and tumor progression. Using gain-and loss-of-function studies, we showed that SRGN promoted NSCLC cells aggressiveness by enhancing stem-like property and EMT in vitro and facilitated tumor growth and colonization in lung and liver in vivo. We further showed that SRGN expression was tightly associated with shortened overall survival in lung cancer patients, suggesting that SRGN may serve as a poor prognostic marker in lung cancer patients.
We showed that SRGN promoted NSCLC aggressive phenotypes in a CD44-dependent manner. In addition, we showed that incubation with purified recombinant SRGN or SRGN-containing CM promoted the migration in CD44-expressing cells, and that incubation with an anti-CD44 neutralizing antibody blocked SRGN-elicited Nanog expression. SRGN in the CM was highly decorated with CS (Supplementary Figure S2b) . CS modification of SRGN has been shown to be critical for its binding to CD44. 20 In our study, treatment of SRGN-containing CM with chondroitinase ABC, which removed CS disaccharide repeats, abolished SRGNelicited cell migration (data not shown). We have also generated a SRGN(S4A) mutant, in which the eight serine residues in the SRGN [S/F-G] repeats were converted to alanine, and our data showed that the low glycosylated SRGN(S/A) mutant protein was readily secreted to the medium, but failed to promote cell Serglycin promotes lung cancer malignancies J-Y Guo et al migration (data not shown). These findings suggested that SRGN binds to tumor cell surface CD44 to promote malignant phenotypes, and that CS modification of SRGN, which mediates its interaction with CD44, is important for its oncogenic function.
In this study, we demonstrated that CD44 is a prerequisite for SRGN-mediated oncogenic activities in promoting stemness, EMT and metastatic tumor formation in vivo. We showed that SRGN binds to CD44 and promotes EMT through NF-κB-mediated CLDN1 expression. CD44 has been shown to mediate HA-induced NF-κB activation via Ras/PKC ζ/IκB signaling axis. 39 SRGN binding domain of CD44 is located close to HA binding domain. 20 We showed that CD44 antibody (5F12), an antibody that was shown to block HA-CD44 interaction, blocked SRGN-elicited Nanog induction in lung cancer cells. It remains to be examined whether SRGN-induced NF-κB activation in lung cancer is mediated through PKC and Ras pathway. Bourguignon et al. 40 have reported that HA binding to CD44 promoted chemoresistance in head and neck squamous cell carcinoma (HNSCC) cells. The authors showed that HA binding to CD44 promoted STAT3 phosphorylation and the interaction of STAT3 and Nanog, leading to increased cell survival. In this study, we showed that SRGN/CD44 axis confers NSCLC cells increased resistance to cisplatin. Our recent data showed that overexpression of SRGN in H1299 cells enhanced STAT3 phosphorylation at Y705 and CD44/STAT3 complex formation and that KD of either CD44 or Nanog efficiently blocked SRGN-mediated cisplatinresistance (data not shown). These data suggested that SRGN/ CD44-elicited cisplatin-resistance was in part mediated through induction of Nanog and activation of STAT3.
CLDN1 is an integral membrane protein of the tight junctions that regulate paracellular permeability. Loss of CLDN1 expression is frequently associated with the disruption of tight junctions and the emergence of EMT in tumor progression. 41, 42 Nevertheless, several studies have recently reported that CLDN1 was frequently overexpressed in various types of cancers, 29, 30, 43, 44 and overexpressed CLDN1 promoted malignant progression by enhancing cell migration/invasion, survival, and metastasis, and inducing EMT. 29, [45] [46] [47] Therefore, CLDN1 appears to have a dual role as a tumor suppressor when expressed in the tight junctions as an epithelial marker, and as a tumor-promoting protein when overexpressed in various human cancers. However, the mechanisms governing the function of CLDN1 being tumor-suppressive or oncogenic remain unclear. In colon cancer, the overexpressed CLDN1 protein was found to have an altered subcellular localization by immunohistochemistry. 29 CLDN1 displays restricted expression to the membrane, typically at the lateral sides of the cells in colon mucosa, but high level of nonjunctional CLDN1 staining was frequently observed in the nucleus and cytoplasm in colon carcinomas and metastatic lesions. These findings suggest an oncogenic role of nonjunctional CLDN1 in malignant progression. Similar observations on the subcellular localization of CLDN1 and its function have been made in lung cancer. Membranous CLDN1 had been demonstrated to suppress lung adenocarcinoma cell migration and was associated with better survival in patients of lung adenocarcinoma. 48 On the other hand, cytosolic CLDN1 was demonstrated to mediate TNFα-induced EMT in lung cancer cells. 31 In this study, we showed that CLDN1 expression was detected in 49.4% of resectable NSCLC, and that all the CLDN1-positive tumors displayed cytosolic and/or nuclear staining. In addition, a strong association of SRGN and CLDN1 expression was observed in primary NSCLC (P o0.001). Our studies suggest that SRGN promoted EMT and malignant phenotypes in lung cancer cells via up-regulating the expression of nonjunctional CLDN1. Most importantly, we showed that SRGN-CLDN1 axis predicts poor prognosis in NSCLC patients.
In summary, we established a direct, functional link between SRGN and CD44 in promoting NSCLC malignancies. We demonstrated that SRGN instigated lung cancer cells aggressiveness and stemness-like properties through NF-κB/CLDN1 axis and Nanog induction in a CD44-dependent manner. In line with these findings, we showed that SRGN serves as a poor prognostic factor in NSCLC. The present study provides valuable information that targeting TME, such as secreted proteoglycan SRGN, may be a potential target for NSCLC cancer therapy.
MATERIALS AND METHODS
Cell culture
Human duodenal adenocarcinoma HTB-40 cells, breast cancer MCF7 and MDA-MB-231 cells, NSCLC H1299, H322, H358, H23, H928, H460 and A549 cells were from ATCC. HTB-40, H1299, H322, H23, H460 and MCF7 cells were cultured in Roswell park memorial institute (RPMI)-1640 medium, and H928, MDA-MB-231 and A549 cells in Dulbecco's modified eagle medium, supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin, and maintained at 37°C in humid air with 5% CO 2 condition. Cell lines were tested routinely to confirm the absence of mycoplasma, and have been recently authenticated by short tandem repeat profiling. /SRGN cells stably harboring scramble-shRNA and Nanog-shRNA were subjected to sphere formation assay. On day 13, phase contrast images of spheres (original magnification, × 100; scale bar: 50 μm) were taken and the % of sphere formation scored. Western blot analysis of Nanog is shown. (f) Unsorted and CD44(À ) cells stably harboring Mock-control and SRGN-expressing vectors were cultured in serum-free medium for 48 h, and subjected to western blot analysis of Nanog expression. (g) Cells described in (f) were subjected to sphere formation assay. On day 13, phase contrast images of spheres (original magnification, × 100; scale bar: 50 μm) were taken, and the % of sphere formation scored. (h) H1299 CD44(À ) cells stably harboring Mock-control and CD44s-expressing vectors were cultured in the presence of CM collected from H1299/Mock or H1299/SRGN cells for 24 h, and subjected to western blot analysis of Nanog expression. (i) Cells described in h were subjected to sphere formation assay in CM collected from H1299/Mock or H1299/SRGN cells supplemented with 1X B27, 20 ng/ml EGF and 20 ng/ml bFGF. On day 13, phase contrast images of spheres (original magnification, × 100; scale bar: 50 μm) were taken, and the percentage of sphere formation scored. (j) Cells were cultured in serum-free medium containing 2 μg/ml of mouse IgG (mIgG) or CD44 antibody (5F12) (MA5-12394, Thermo Fisher Scientific, Waltham, MA, USA) for 24 h, and subjected to western blot analysis of Nanog expression. (k) Cells were seeded at 1 × 10 4 cells/well in 96-well plates, and treated with cisplatin at designated concentrations for 72 h (upper panel) and with 5 μM cisplatin for designated time (lower panel), and cell viability was assessed using Cell Counting Kit-8. (l) Cells (2 × 10 4 cells/ well) were cultured in serum-free medium in 6-well ultra-low attachment plates. After 48 h, cells were stained by trypan blue and viable cells were counted. Data are presented as the mean ± s.d. of three independent experiments. **P o0.01 and ***Po0.001 by Student's t-test.
Construct, transfection and establishment of cells stably expressing SRGN SRGN (NM_002727) full-length cDNA was generated by polymerase chain reaction using cDNA derived from 293T cells as template. The PCR product was subcloned into p3XFLAG-CMV-13 vector (Sigma-Aldrich), followed by sequence confirmation. To establish stable clones, H1299 cells were transfected with p3XFLAG-CMV-13-SRGN or p3XFLAG-CMV-13 plasmid alone by LF2000 (Life Technologies), and cultured in medium containing G418 (800 μg/ml, Sigma-Aldrich) for 14 days.
RNA isolation, RT-PCR and quantitative PCR
Total RNA was prepared from homogenized tissues or cells and converted to cDNA as described previously. 49 Quantitative PCR was performed as described, 49 using primers for SRGN (forward primer, 5′-CGCTGCAATCC AGACAGTAA-3′; reverse primer, 5′-TCCCAGATCCTGATCCAGAG-3′), CD44 (forward primer, 5′-CCGACAGCACAGACAGAATC-3′; reverse primer, 5′-AAGAGGGATGCCAAGATGATC-3′), OCT4 (forward primer, 5′-AGTGAG AGGCAACCTGGAGA-3′; reverse primer, 5′-ACACTCGGACCACATCCTTC-3′), SOX-2 (forward primer, 5′-CATCACCCACAGCAAATGAC-3′; reverse primer, 5′-CAAACTTCCTGCAAAGCTCC-3′), Nanog (forward primer, 5′-TTCCTTCC TCCATGGATCTG-3′; reverse primer, 5′-TCTGCTGGAGGCTGAGGTAT-3′) and GAPDH (forward primer, 5′-TGGTATCGTGGAAGGACTCATGAC-3′; reverse primer, 5′-ATGCCAGTGAGCTTCCCGTTCAGC-3′). The threshold cycles (C T ) were recorded for all samples. Lentivirus-based shRNA knockdown approach pLKO.1 plasmids encoding shRNA with scramble sequence (TRCN005: 5′-AGTTCAGTTACGATATCATGT-3′) or sequences targeting human SRGN (TRCN0000297801: 5′-GCTGCAATCCAGACAGTAATT-3′), Nanog (TRCN000 0004887: 5′-CCTGGAACAGTCCCTTCTATA-3′) or CLDN1 (#1, TRCN0000 117332: 5′-GCATCGTTATTAAGCCCTTAT-3′; and #2, TRCN0000117336: 5′-GCCACAGCATGGTATGGCAAT-3′) were purchased from the National RNAi Core Facility, Taiwan. Lentivirus production and KD approach have been previously described. 50 Migration and invasion assays Cells were cultured in serum-free medium for 24 h, re-suspended in serumfree medium, and subjected to migration/invasion assays using the standard 48-well chemotaxis chamber as described previously. 51 Cells were seeded in the upper chamber (3 ×10 3 cells in 50 μl per well), and medium containing 5% fetal bovine serum was added to the lower chamber. For invasion assay, the upper surface of membrane (GE Healthcare Life Sciences, K80SH58050) inserted between the two chambers was coated with matrigel (3.37 μg/μl). In several experiments, cells were re-suspended in serum-free medium containing recombinant SRGN (5 μg/ml) or in SRGNcontaining CM. Migrated cells were counted in 3 h for migration and 18 h for invasion assays.
Sphere formation assay
Cells (100 cells/well) were seeded in eight replicates in Ultra-low attachment 96-well plates (Corning), and cultured with serum-free RPMI medium supplemented with B27 (Invitrogen), EGF (20 ng/ml, Invitrogen), and bFGF (20 ng/ml, Invitrogen) for 7 (for H460) or 13 (for H1299) days. Percentage of cells forming spheres with diameter 450 μm was calculated.
Anchorage-independent growth assay Anchorage-independent cell growth in soft agar has been previously described. 52 NF-κB luciferase reporter assay Cells were transiently transfected with pGL4.32[luc2P/NF-κB-RE] (Promega) and pGL4.74[hRluc/TK] vectors (Promega) using LF2000 (Life Technologies) in serum-free Opti-MEM for 24 h, followed by culturing in serum-free RPMI for an additional 24 h, and cells were harvested for luciferase activity measurement by Dual-Luciferase Assay kit (Promega) as described. 
Nuclear and cytosolic fractionation
Cells were incubated with serum-free medium for 48 h, and nuclear and cytosolic fractions were prepared as described. 53 Animal studies All experimental procedures were carried out in accordance with approved guidelines of the Institutional Animal Care and Utilization Committee at Academia Sinica, Taiwan. Six-week-old male nude and NOD-SCID IL2Rγ null (NSG) mice were purchased from the National Laboratory Animal Center, Taiwan. Mice were randomized for xenograft tumor growth and experimental metastasis assays. For xenograft tumor formation, 1 × 10 6 cells were subcutaneously injected to the right flank of the mice (10 mice/ group). Tumor size was measured by scalper weekly and tumor volume was calculated according to the formula: volume = length × width 2 × 0.52. For experimental metastasis assay (5 mice/group), 2 × 10 6 cells were injected into the tail vein of nude mice or NOD-SCID IL2Rγ null (NSG) mice (for H1299 cells). Tumor colonization in the lung and liver were assessed after 5 weeks. Liver and lung tissues were fixed in 4% Bouin solution. Liver nodules were counted. Lung sections were subjected to hematoxylin and eosin staining, and analyzed using MetaMorph software.
Patient samples
All studies were approved by the Institutional Review Board of Academia Sinica, Taiwan. Paired tumorous and corresponding adjacent nontumorous tissues were derived from patients who underwent surgical 
